<DOC>
	<DOC>NCT00964535</DOC>
	<brief_summary>The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbohaler in terms of the drug absorbed into the bloodstream.</brief_summary>
	<brief_title>Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Males or females aged 1860 years with documented diagnosis of asthma Prebronchodilator forced expiratory volume in one second (FEV1) at least 80% of the predicted value The asthma should be stable on the same regular treatment for at least 4 weeks before screening. Use of oral, parenteral or rectal corticosteroids within 4 weeks preceding the screening Respiratory infection within 4 weeks preceding the screening Any condition requiring regular concomitant treatment or likely to need concomitant treatment during the study with medicinal products which have pharmacokinetic interactions with budesonide Any disorder or clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>